Tevogen Bio Appoints Esteemed Global Safety Management Expert Victor Sordillo to its Corporate Advisory Board


Tevogen Bio Appoints Esteemed Global Safety Management Expert Victor Sordillo to its Corporate Advisory Board


  • Victor Sordillo, PE, CSP, MBA, joins Tevogen Bio’s Corporate Advisory Board


  • The appointment of Sordillo contributes to the diversity of thought leadership within Tevogen Bio’s executive team by way of expertise in leadership, risk management, and finance as well as his previous roles on Boards of various charitable organizations such as the American Red Cross and United Way


Victor Sordillo, PE, CSP, MBA, joins Tevogen Bio’s Corporate Advisory Board



August 31, 2022


WARREN, N.J.–(BUSINESS WIRE)–Tevogen Bio, a late-stage clinical biotechnology company specializing in the development of cell and gene therapies in oncology, neurology, and virology, is pleased to announce the appointment of Victor Sordillo, PE, CSP, MBA, to Tevogen’s Corporate Advisory Board.


With over 35 years of experience in risk engineering, Sordillo currently serves as an Executive Vice President at Sompo International, leading a global team of experienced risk control professionals which specialize in residential, commercial, and industrial accounts. He previously was the Senior Vice President of Risk Solutions for QBE North America, as well as the Global Technical Services Manager for Chubb.


Previously, Sordillo served on the Boards of Directors of charitable organizations such as United Way and the American Red Cross. In 2019, he was honored by the American Society of Safety Professionals with a lifetime achievement of 40 years of dedication to safety.



“I am thrilled to be joining Tevogen Bio as a member of its Corporate Advisory Board,” said Sordillo. “It’s an honor to have the opportunity to provide insight and leadership alongside other members of the Board, and I look forward to contributing to Tevogen’s patient-centric mission to develop convenient and affordable immunotherapies for large patient populations while continuing the expansion of the company’s novel and disruptive biotech business model which integrates affordability with business sustainability.”



“Victor’s addition to the Corporate Advisory Board will allow us to leverage his vast industry expertise, commitment to increasing the accessibility of lifesaving medications, and compassionate spirit, as we continue to pioneer the next era of medical innovation,” said Tevogen CEO, Ryan Saadi, M.D., M.P.H.


In addition to holding senior global leadership positions at two major international insurance organizations, Sordillo has provided his expertise to the U.S. Army Corps of Engineers. He has been a guest speaker at many different venues including the American Society of Civil Engineers, AICPA CFO’s annual meeting and the ASSP seminar program. Sordillo has been serving as the Mayor of Warren, NJ, for more than 22 years. He graduated with a Bachelor of Science from Tufts University, and his Master of Business Administration in International Business from the University of Massachusetts Lowell.




About Tevogen’s Next Generation Precision T Cell Platform


Tevogen’s next generation precision T cell platform is designed to provide increased specificity to eliminate malignant and virally infected cells, while allowing healthy cells to remain intact. Multiple targets are selected in advance with the goal of overcoming mutational capacity of cancer cells and viruses.


Tevogen is investigating its technology’s potential to overcome the primary barriers to the broad application of personalized T cell therapies: potency, purity, production-at-scale, and patient-pairing, without the limitations of current approaches. Tevogen’s goal is to open the vast and unprecedented potential of developing personalized immunotherapies for large patient populations impacted by common cancers and viral infections.


Tevogen recently announced that it completed enrollment in the Proof-of-Concept clinical trial of its lead product, TVGN-489, for ambulatory, acute-risk COVID-19 patients, with no dose-limiting toxicities or significant treatment-related adverse events observed for any patient at any dose level.


TVGN-489 is a genetically unmodified, off-the-shelf, allogeneic cytotoxic CD8+ T lymphocyte (CTL) product with activity against multiple, precise targets across the SARS-CoV-2 genome.




About Tevogen Bio


Tevogen Bio is driven by a team of distinguished scientists and highly experienced biopharmaceutical leaders who have successfully developed and commercialized multiple franchises. Tevogen’s leadership believes that accessible personalized immunotherapies are the next frontier of medicine, and that disruptive business models are required to sustain medical innovation in the post-pandemic world.




Forward-Looking Statements


This press release contains certain forward-looking statements relating to Tevogen Bio™ Inc (the “Company”) and its business. These statements are based on management’s current expectations and beliefs as of the date of this release and are subject to several factors which involve known and unknown risks, delays, uncertainties, and other factors not under the Company’s control that may cause actual results, performance or achievements to be materially different from the results, performance or other expectations implied by these forward-looking statements. Forward-looking statements can sometimes be identified by terminology such as “may,” “will,” “should,” “intend,” “expect,” “believe,” “potential,” and “possible,” or their negatives or comparable terminology, as well as other words and expressions referencing future events, conditions, or circumstances. In any forward-looking statement in which the Company expresses an expectation or belief as to future results, there can be no assurance that the statement or expectation or belief will be achieved. Various factors may cause differences between the Company’s expectations and actual results, including, among others: the Company’s limited operating history; uncertainties inherent in the execution, cost, and completion of preclinical studies and clinical trials; risks related to regulatory review, and approval and commercial development; risks associated with intellectual property protection; and risks related to matters that could affect the Company’s future financial results, including the commercial potential, sales, and pricing of the Company’s products. Except as required by law, the Company undertakes no obligation to update the forward-looking statements or any of the information in this release, or provide additional information, and expressly disclaims any and all liability and makes no representations or warranties in connection herewith or with respect to any omissions therefrom.






Katelyn Joyce
Corporate Communications Lead
T: 1 877 TEVOGEN, Ext 709